A message from our friends at i2i Marketing Group, LLC 
The Military Budget Is Near $1T - This Sits at the Center Ammunition. Missile systems. Night vision. One metal runs through all of it. And most of the world's supply sits in the hands of geopolitical rivals like China and Russia. America is on the look out for its own sources. Defense budgets are rising. Export restrictions have tightened. Governments are building their own reserves. When military supply chains depend on foreign rivals, secure North American deposits can suddenly become a strategic advantage. That's why a high-grade deposit just miles from the U.S. border is starting to draw attention. Drilling is underway and somehow the market hasn't fully caught up yet. Discover the company advancing this strategic deposit > 
This Month's Featured Story 3 Blue-Chip Stocks Built for a Rotating MarketAuthored by Chris Markoch. Posted: 3/8/2026. 
Key Points - Sector rotation in 2026 is favoring defensive, value-oriented areas such as utilities, healthcare, and consumer staples over mega-cap technology.
- Duke Energy and Gilead Sciences combine defensive characteristics with identifiable growth catalysts and reliable dividends.
- Hershey has rallied sharply with consumer staples, but its valuation now looks stretched relative to its earnings profile.
- Special Report: RIP America: Drowned in Debt (From Porter & Company)
 Sector rotation occurs when investors move money out of sectors that look overbought and into ones that seem undervalued. In 2026, that has generally meant rotating away from mega-cap technology names and into value-oriented, defensive sectors such as energy and consumer staples. The key word is "overvalued." Big tech has been running hot for more than two years, largely driven by the emergence of artificial intelligence (AI). Despite concerns of a dot-com–style repeat, investors largely overlooked the lofty valuations of many of these stocks. In this short 3-min. video, legendary investor James Altucher reveals the name and ticker symbol of a company he believes will skyrocket as soon as March 26th…
That would make it the biggest IPO in history! Click here to check it out before it's too late. But investors who believed this time was different are finding that valuation often doesn't matter—until it does. As the economy begins to heat up, money is flowing to other areas, including blue-chip defensive names like the stocks highlighted below. Utilities Provide Stability in a Rotating Market Duke Energy (NYSE: DUK) is a logical beneficiary of sector rotation. Duke is a major utility provider in the Southeastern and Midwestern United States. Utility stocks are among the most defensive, typically viewed as value and income investments. Duke Energy offers an attractive, relatively secure dividend yielding about 3.2% and has raised its payout for 20 consecutive years. The evolving U.S. energy landscape also creates growth opportunities for DUK. The company follows an “all of the above” approach to power generation, including nuclear, hydroelectric and natural gas. Natural gas has driven the stock's strong bounce in 2026, but Duke's stable residential utility revenue and projected growth in areas such as power for data centers are attracting rotation flows. DUK is up nearly 12% year-to-date in 2026, putting it within about 5% of the consensus price target of $136.87, a level that would push the stock above its 52-week high. At roughly 20.5x earnings, it trades at a slight premium to its historical average. Since the company's February earnings report, analysts have raised price targets amid expectations for strong year-over-year revenue growth in the second half of the year—an outlook that could support a bullish re-rating. Biotech Strength Gives Gilead Defensive Growth Some analysts expect biotechnology stocks to benefit from the current rotation. Gilead Sciences (NASDAQ: GILD) offers defensive growth within healthcare, a sector that has largely underperformed the broader market. Gilead is a leading provider of HIV therapies, with key drugs protected by patents into the 2030s. Investors are also encouraged by a pipeline that includes more than 50 candidates. Beyond HIV, Gilead expects to launch anito-cel, a CAR-T therapy for multiple myeloma, in 2026 and may see a label expansion for its breast cancer drug, Trodelvy. GILD is up nearly 18% in 2026, reaching a 52-week high and now trading slightly below that peak—likely profit taking after an outsized run and a potential buy-the-dip opportunity. Analysts' consensus price target of $156.72 implies more than an 8% upside. Since the February earnings report, several analysts have raised targets, with the highest estimates near $170. Gilead also pays a reliable dividend, yielding about 2.28%, and has increased its payout for 10 consecutive years. Consumer Staples Rally Lifts Hershey Stock The Hershey Company (NYSE: HSY) has been one of the biggest beneficiaries of the 2026 rotation into consumer staples stocks. HSY is up nearly 25% year-to-date and has broken out of a bearish trend that began in 2023. Beginning in 2023, Hershey grappled with elevated cocoa costs that persisted into 2025 and will continue to weigh on 2026 earnings. Still, the market looks forward, and analysts forecast solid earnings and revenue growth this year. HSY is trading above the consensus price target of $222.21, but analysts have been raising targets since the February earnings report. The most bullish call comes from Goldman Sachs, which has a $267 target. In that report, Hershey raised its dividend by 5.9%, marking 15 consecutive years of increases. The dividend yields around 2.5% and the company pays $5.81 per share annually. Following the recent run-up, HSY trades at over 50x earnings—likely a reason for the heavy institutional selling last quarter, but it may also present investors with another entry point into this sweet stock.
| 
